Core Viewpoint - The company has made significant progress in its innovative transformation, focusing on drug development in oncology, liver disease/metabolism, respiratory, and surgical/pain management, with multiple pipelines showing potential for overseas licensing [1][2][3] Group 1: Innovation and R&D Investment - The company has increased its R&D investment to 17.6% of revenue in 2024, up from 9.9% in 2019 [2] - By the end of 2024, the company has received approval for 17 innovative drugs, with innovative product revenue accounting for 42% of total revenue, compared to 11% in 2015 [2] - The company has averaged over 3 License in transactions per year from 2019 to 2024, enhancing the richness of its innovative drug pipeline [2] Group 2: Product Pipeline and Market Potential - The oncology pipeline includes key products such as Anlotinib, which has received approval for 9 indications and has 4 additional indications submitted for NDA [3] - The company is advancing several promising products, including TQB2102 (HER2 dual antibody ADC) and TQC3721 (PDE3/4 inhibitor), which have significant potential for overseas licensing [3] - The company’s biosimilar drugs have a combined market capacity of 240 billion yuan in 2024, indicating strong growth potential [3][4] Group 3: Financial Projections and Valuation - The company expects revenue growth of 11.4%/10.5%/9.6% for 2025E/26E/27E, with adjusted net profit growth of 12.2%/11.5%/10.5% [4] - The target price is set at 9.40 HKD based on a 10-year DCF model, corresponding to a 37x adjusted PE for 2026 [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物製藥有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.025 HKD | | 750,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 30,000,000,000 | | HKD | | 0.025 HKD | | 750,000,000 | 本月底法定/註冊股本總額： HK ...

格隆汇8月1日丨中国生物制药(01177.HK)宣布，公司将于2025年8月18日（星期一）举行董事会会议， 藉以批准（其中包括）刊发公司及其附属公司截至2025年6月30日止六个月期间的未经审核中期业绩， 以及考虑派发中期股息（如有）。 ...

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 董事會召開通知 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國生物製藥有限公司 公司秘書 陳凱年 香港，二零二五年八月一日 於本公告日期，本公司董事會包括六位執行董事，即謝其潤女士、謝炳先生、鄭翔玲女士、謝承潤 先生、謝炘先生及田舟山先生，以及五位獨立非執行董事，即陸正飛先生、李大魁先生、魯紅女 士、張魯夫先生及李國棟醫生。 中國生物製藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二五年八月十八日 （星期一）舉行董事會會議，藉以批准（其中包括）刊發本公司及其附屬公司截至二零二五年六月三十日 止六個月期間之未經審核中期業績，以及考慮派發中期股息（如有）。 承董事會命 ...

本文源自：金融界 作者：行情君 截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。 8月1日，中国生物制药(01177)盘中下跌2.13%，截至13:10，报7.36元/股，成交5.19亿元。 中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生 产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗 领域具有优势。公司自从2000年上市以来，在MSCI全球标准指数、恒生指数等多个指数中成为成分 股，连续六年入选《制药经理人》的"全球制药企业TOP50"，核心企业正大天晴药业集团、北京泰德制 药股份有限公司多年位列中国医药工业企业百强榜，公司产品收入占比逐年提升。 ...

Core Viewpoint - CMB International initiates coverage on China Biopharmaceutical with a "Buy" rating and a target price of HKD 9.4 based on a 10-year DCF model, corresponding to a 2026 adjusted P/E ratio of 37 times [1] Group 1: Company Performance - The company is entering a harvest period for innovative drugs, with rapid growth in biosimilars and stable performance in chemical generics [1] - Currently, the company has received approval for 7 biosimilars, with a total market capacity of RMB 24 billion in sample hospitals for 2024 [1] - The mature sales network in China is expected to facilitate rapid sales growth for biosimilars, particularly for the first generic version of Pertuzumab [1] Group 2: Financial Projections - CMB International forecasts revenue growth of 11.4%, 10.5%, and 9.6% for the years 2025, 2026, and 2027, respectively [1] - Adjusted net profit is projected to grow by 12.2%, 11.5%, and 10.5% for the same years [1] - The current forecasts do not account for potential contributions from several significant innovative products that may receive overseas licensing [1]

Group 1 - The core point of the article is that China Biopharma has successfully progressed in its collaboration with Merck on LM-299, with a milestone payment of $300 million expected to be received soon [1] - The technology transfer for LM-299 was completed in July 2023, and Merck anticipates recognizing the $300 million milestone payment in the third quarter [1] - In 2024, China Biopharma and Merck reached a global exclusive licensing agreement for LM-299, which includes an upfront payment of $588 million and potential milestone payments of up to $2.7 billion [1]

Core Viewpoint - The report from CMB International initiates coverage on China Biopharmaceutical (01177) with a "Buy" rating, setting a target price of HKD 9.40 based on a 10-year DCF model with a WACC of 9.3% and a perpetual growth rate of 2.0% [1] Group 1: Financial Projections - Revenue is expected to grow by 11.4%/10.5%/9.6% in 2025E/26E/27E, while adjusted net profit is projected to increase by 12.2%/11.5%/10.5% during the same period [1] Group 2: Innovation and R&D - The company is significantly increasing its R&D investment, with an expected 17.6% of revenue allocated to R&D in 2024, up from 9.9% in 2019 [1] - By the end of 2024, the company will have received approval for 17 innovative drugs, with innovative product revenue accounting for 42% of total revenue, compared to 11% in 2015 [1] - The company has been actively engaging in License in transactions, averaging over 3 deals per year from 2019 to 2024, enhancing its innovative drug pipeline [1] Group 3: Product Pipeline and Market Potential - The company has several products with potential for overseas licensing collaborations, including TQC3721, Rovafixitinib, TQB2102, TQB3616, TQA2225, LM-108, LM-168, and LM-364 [1] - The innovative R&D focuses on four key areas: oncology, liver disease/metabolism, respiratory, and surgical/pain management, with a rich pipeline of innovative drugs [2] - Anlotinib has become a cornerstone product with 9 approved indications and 4 NDA submissions, further expanding its sales potential through combination therapies [2] Group 4: Biosimilars and Generic Drugs - The company has 7 approved biosimilars with a total market capacity of RMB 24 billion in 2024, and sales are expected to grow rapidly, particularly for the first generic version of Pertuzumab [3] - The chemical generic drug business has shown resilience during recent policy adjustments, with a projected revenue growth of 3.1% YoY in 2024 [3] - The impact of centralized procurement on generic drugs has largely dissipated, with the tenth batch of centralized procurement accounting for only 1% of the company's total revenue in 2024 [3]

Core Viewpoint - 招银国际 initiates coverage on China Biopharmaceutical (01177) with a "Buy" rating, setting a target price of HKD 9.40 based on a 10-year DCF model with a WACC of 9.3% and a perpetual growth rate of 2.0% [1] Group 1: Innovation and R&D - The company is undergoing a comprehensive transformation towards innovation, with R&D expenditure expected to account for 17.6% of revenue in 2024, up from 9.9% in 2019 [2] - By the end of 2024, the company will have received approval for 17 innovative drugs, with innovative product revenue contributing 42% of total revenue, compared to 11% in 2015 [2] - The company has increased its focus on License in transactions, averaging over 3 deals per year from 2019 to 2024, enhancing its innovative drug pipeline [2] Group 2: Product Pipeline and Market Potential - The company’s innovative R&D focuses on four key areas: oncology, liver disease/metabolism, respiratory, and surgical/pain management, resulting in a rich pipeline [3] - Anlotinib has become a cornerstone product in oncology, with 9 approved indications and 4 NDA submissions as of July 2025, and is expected to expand into first-line treatment through combination with immunotherapy [3] - The company has several products with potential for overseas licensing, including TQC3721, Rovafatinib, TQB2102, and others, indicating strong prospects for international collaboration [2][3] Group 3: Biosimilars and Generic Drugs - The company has received approval for 7 biosimilars, with a total market capacity of RMB 24 billion in 2024, and is expected to see rapid sales growth, particularly for the first biosimilar of Pertuzumab [4] - The chemical generic drug business has shown resilience during recent policy adjustments, with a projected revenue growth of 3.1% YoY in 2024 [4] - The impact of generic drug procurement policies has largely dissipated, with the tenth batch of procurement accounting for only 1% of the company’s total revenue in 2024 [4]

Investment Rating - The report initiates coverage with a "Buy" rating and sets a target price of HKD 9.40, indicating a potential upside of 24.9% from the current price of HKD 7.52 [1][3][23]. Core Insights - The report highlights the significant achievements of the company in its transformation from generic to innovative pharmaceuticals, focusing on key therapeutic areas such as oncology, liver disease/metabolism, respiratory, and surgical/pain management [1][9][26]. - The company has increased its R&D investment, with R&D expenses projected to reach RMB 5.09 billion in 2024, accounting for 17.6% of revenue, up from 9.9% in 2019 [10][40]. - The innovative product pipeline has expanded significantly, with 17 approved innovative drugs by the end of 2024, and the revenue contribution from innovative products is expected to reach 50% by 2025 and 60% by 2027 [10][47]. Financial Summary - For FY23A, the company reported sales revenue of RMB 26.199 billion, with a projected growth of 10.2% in FY24A [2]. - Adjusted net profit for FY23A was RMB 2.589 billion, with an expected increase of 33.5% in FY24A [2]. - The adjusted earnings per share (EPS) is forecasted to grow from RMB 0.14 in FY23A to RMB 0.19 in FY24A [2]. Market Performance - The company's market capitalization is approximately HKD 141.08 billion, with an average trading volume of HKD 860.8 million in March [3]. - The stock has shown strong performance, with a 166.7% increase over the past six months [5]. Product Pipeline and Innovation - The company has a robust pipeline with multiple products showing potential for overseas licensing, including TQC3721, 罗伐昔替尼, and TQB2102 [12][27]. - The oncology segment is highlighted as a key growth area, with 安罗替尼 being a cornerstone product that has received multiple indications and is expected to generate significant sales [13][14]. Business Strategy - The company is focusing on enhancing its supply chain and production efficiency, achieving a procurement coverage rate of 95% by 2024 [28]. - A strategic shift towards a more specialized sales structure has been implemented to improve marketing effectiveness and operational efficiency [33]. Growth Projections - Revenue is expected to grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2027, driven by innovative product sales and a strong pipeline [23][24]. - Adjusted net profit is projected to increase at a CAGR of 11.4% during the same period [24].